Burning Rock Biotech
BNR
20 hedge funds and large institutions have $15.1M invested in Burning Rock Biotech in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
5% more funds holding
Funds holding: 19 → 20 (+1)
0.03% more ownership
Funds ownership: 2.48% → 2.51% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less capital invested
Capital invested by funds: $19M → $15.1M (-$3.92M)
88% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$790K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$10.5K |
| 4 |
JP Morgan Chase
New York
|
+$1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$67 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$347K |
| 2 |
RWMG
Redwood Wealth Management Group
Medford,
New Jersey
|
-$102K |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$63.1K |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$63.1K |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$15.2K |
BNR Hedge Fund Activity: Q1 2024 in Review
20 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q1 2024, worth a combined $15.1M — down 21% from $19M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BNR positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 8 trimmed.
The largest buyer was Kynam Capital Management, adding an estimated $790K. The largest seller was Morgan Stanley, cutting an estimated $347K.
- 20 institutional investors held Burning Rock Biotech (BNR) as of Q1 2024, up from 19 in Q4 2023.
- Funds reported $15.1M of Burning Rock Biotech stock for Q1 2024, down 21% quarter-over-quarter.
- 4 funds opened new Burning Rock Biotech positions in Q1 2024 and 3 closed out, a net change of +1 holder.
- The largest Burning Rock Biotech buyer in Q1 2024 was Kynam Capital Management, an estimated $790K added.
- The largest Burning Rock Biotech seller in Q1 2024 was Morgan Stanley, an estimated $347K sold.
Based on aggregated 13F filings for Q1 2024.